Evaluation of medication changes following severe COVID-19 infection: a multicentre evaluation.

Pamela MacTavishJoanne Michelle McPeakeAntoin BreslinRuth ForrestRakesh KishoreFiona MacGregorAlison OpreyTara QuasimMartin Shaw

Published in: BMJ open respiratory research (2021)

Following severe COVID-19, patients may require new or increasing doses of medicines. Ongoing review of these patients is crucial to ensure optimal outcomes.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
sars cov
clinical trial
healthcare
prognostic factors
randomized controlled trial
metabolic syndrome
study protocol
drug induced
adipose tissue
weight loss
insulin resistance
patient reported
glycemic control